Agreement

2011 Livestock Products Distribution Agreement

EXHIBIT 1.1
 
[CONFIDENTIAL TREATMENT REQUESTED] /*/ INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 
 
2011 LIVESTOCK PRODUCTS DISTRIBUTION AGREEMENT
 
    This Livestock Products Agreement (“Agreement”) effective as of January 1, 2011 (“Effective Date”) is made by and between Pfizer Inc., 5 Giralda Farms, Madison, New Jersey 07940-1027 (“Pfizer”) and Walco International, Inc., 7 Village Circle, Suite 200, Westlake, TX 76262 (hereinafter, “WALCO”).
 
WHEREAS, WALCO is in the business of buying and selling animal health products and servicing customers for those products, and
 
WHEREAS, WALCO and Pfizer wish to set forth the terms of their relationship related to the purchase and supply of such products,
 
NOW, THEREFORE, in consideration of the promises and covenants contained herein, the parties hereby agree as follows:
 
Definitions:
 
“PARTICIPATING CUSTOMERS” shall mean customers from the list of customers approved by Pfizer who have entered into a Leaders Edge Agreement with Pfizer.
 
“Products” shall mean the Pfizer cattle and swine products sold to WALCO by Pfizer pursuant to this Agreement (and referenced in Schedule A to this Agreement).
 
“Sales Out” shall mean the reported sales by WALCO to Covansys and accepted by Pfizer.
 
“Strategic Accounts” shall mean all those PARTICIPATING CUSTOMERS listed in Schedule B hereto.
 
1.   (a) Pfizer shall continue to promote its Products to certain select customers in the livestock field. The parties agree that each time a PARTICIPATING CUSTOMER selects WALCO as their supplier and to service that customer’s account, Pfizer shall send to WALCO a Pfizer Suggested Resale Price List which shall specify the Pfizer Products and the Pfizer suggested resale prices quoted to such PARTICIPATING CUSTOMER (hereafter “SUGGESTED RESALE PRICE LIST”). Each such SUGGESTED RESALE PRICE LIST shall be incorporated into and become part of this Agreement. Please find the current SUGGESTED RESALE PRICE LIST listed on Schedule C hereto. Also included on Schedule C is the current Pfizer Livestock Distributor Pricing. The Products and suggested resale prices are subject to change at any time in Pfizer’s sole discretion upon thirty (30) days prior written notice.
 
    (b) Pfizer reserves the right to add or delete PARTICIPATING CUSTOMERS or Strategic Accounts at any time at Pfizer’s sole discretion. Pfizer will provide written notice to WALCO of any changes. Pfizer will notify WALCO of any (i) additions to the Strategic Accounts list within twenty-four (24) hours of Pfizer’s receipt of the customer contract and (ii) removals from the Strategic Accounts list within four (4) business days prior to the removal effective date.
 
2.    (a) WALCO represents and warrants that for the purposes of this Agreement, it is in the business of purchasing Products from Pfizer for the sole purpose of resale and distribution, is registered within the state(s) with which it does business, is compliant with all pharmacy and distribution licensing requirements within the state(s) with which it does business, and is compliant with and capable of participating in Electronic Data Interchange (EDI).
 
    (b) WALCO agrees to purchase from Pfizer, at credit terms agreed to between the parties and as may be further set forth on Pfizer’s invoices, Products sufficient to fulfill demand from all customers to whom WALCO will sell Products in the quantities desired by the customers. 
 
 

 
    (c) WALCO agrees to maintain an inventory of Products equal to /*/ Demand per species as identified on Schedule A Cattle and Swine, but excluding all Products indicated on Schedule A as ineligible for RSA payments. /*/
 
       All Products shall count towards the amount held in inventory by WALCO. WALCO and Pfizer agree to act in good faith to resolve any material differences in the on hand inventory calculations.
 
    (d) Pfizer reserves the right to allocate purchases such that WALCO may not purchase more than two (2) months WALCO’s average of the most current Moving Annual Total sales purchases. Exceptions must be approved by Pfizer’s Animal Health Headquarters.
 
    (e) WALCO agrees that all sales of Pfizer Products from WALCO to a PARTICIPATING CUSTOMER shall reflect the specific prices for each Product provided for in that PARTICIPATING CUSTOMER’S most recent SUGGESTED RESALE PRICE LIST. In the event that the price listed on a PARTICIPATING CUSTOMER’S most recent SUGGESTED RESALE PRICE LIST for any particular Product is lower (at the time of consummation of a sale of such particular Products between WALCO and that PARTICIPATING CUSTOMER) than the price paid by WALCO to Pfizer for such Product, Pfizer agrees to credit WALCO's account for the amount of such difference.
 
3. Nothing herein contained shall create or be deemed to create any relationship between the parties other than as specifically provided for herein. No employment, partnership, specific or general agency relationship shall exist unless specifically provided for in writing between the parties. WALCO shall not represent, directly or indirectly, expressly or by implication, that any such relationships exist and/or that WALCO has any authority except as set forth in this Agreement.
 
4. WALCO shall use commercially reasonable efforts to provide appropriate service to the customers to whom WALCO will sell hereunder. For customers serviced pursuant to this Agreement, WALCO shall:
 
    (a) Store its inventory of Pfizer Products under conditions (including refrigeration where appropriate) in accordance with package labeling or other written instructions from Pfizer to ensure that such Products retain their potency, purity, quality, and identity;
 
    (b) Provide to Covansys by the close of business on Friday of each week an EDI report 852 report covering all Product inventory purchased from Pfizer and setting forth in dollars at WALCO’s acquisition cost from Pfizer the amount of inventory by species. WALCO agrees that Pfizer shall have the right, upon reasonable advance notice and during business hours to audit inventory in the possession of WALCO to confirm compliance with this paragraph 4(b) and to confirm the accuracy of the data contained in the report;
 
    (c) Provide to Covansys its Health Industry Number, Customer Health Industry Number, Pfizer Product number, transaction date, ship to zip code, number of units and price with respect to each sale of Product, and unit inventories on each Pfizer Product sku that WALCO sells;
 
    (d) Provide Sales Out data, which shall include Leaders Edge and Non-Leaders Edge sales, to Covansys within ten (10) working days of the date of each invoice. WALCO will use its best efforts to ensure Sales Out data integrity and timeliness;
 
    (e) Submit all orders to Pfizer via EDI. EDI report 867 is the acceptable format;
 
    (f) Establish any service fee or other charge or discount to any customer including PARTICIPATING CUSTOMERS for Pfizer Products independently and at its sole discretion;
 
    (g) Provide regularly scheduled delivery service to its customers and use commercially reasonable efforts to anticipate its customers' requirements for Pfizer Products. In the event Pfizer delivers any product order to PARTICIPATING CUSTOMERS (drop ship), no consideration shall be payable to WALCO for that order under paragraph 5 below, provided that Pfizer will pay WALCO for any drop ship if such shipment is made necessary by the unavailability of Pfizer Products;
 
 
 

 
    (h) WALCO agrees that credit limits established by Pfizer shall be subject to change upon written notice by Pfizer in its sole discretion and that no Product shipments will be made to WALCO in excess of the established credit limits;
 
    (i) Invoice customers in an accurate and timely manner;
 
    (j) Refer to that PARTICIPATING CUSTOMERS SUGGESTED RESALE PRICE LIST on each invoice for Pfizer Products;
 
    (k) Take no action, whether or not identified above, that would harm the Goodwill or name of Pfizer, or damage the interests of Pfizer or the Products, other than where supported by sound factual evidence, including, but not limited to, the diversion of Products and statements of false information. For purposes of this Agreement “Goodwill” shall mean the marketplace advantage of customer patronage and loyalty developed with continuous business under the same name over a period of time; and
 
    (l) /*/
 
5. All sales of Products to PARTICIPATING CUSTOMER or Strategic Accounts for whom a SUGGESTED RESALE PRICE LIST has been incorporated into this Agreement are covered by this Agreement with regard to compensation payable to WALCO hereunder. Any transaction involving Products with any customer including a PARTICIPATING CUSTOMER for which WALCO has not been selected by that PARTICIPATING CUSTOMER as the distributor are not covered by this Agreement with regard to compensation payable hereunder.
 
6.    (a) WALCO shall not be provided with any rebate, discount or other compensation for Products handled under this Agreement unless specifically set forth herein. WALCO will NOT be eligible to collect an RSA on any lateral sales to an unauthorized Pfizer distributor. (It is WALCO's obligation to confirm with Pfizer, prior to making a sale, as to whether a distributor is an authorized distributor.) All sales by Pfizer to WALCO shall be at the then current Pfizer list price but subject to appropriate credits in accordance with paragraph 2(e). Pfizer shall have the right to raise or change the price of any or all Products to WALCO on /*/ prior written notice. Pfizer shall be free to limit sales of any or all Products to WALCO in advance of any price increase.
 
    (b) The parties agree that Pfizer shall not be obligated to issue credits for any returns that exceed the current average of returns of distributors as specified below unless such returns are the subject of a recall or made at the request of Pfizer. The current average of returns of distributors for the calendar year of the contract timeline January 1, 2011 to December 31, 2011 shall be:
 
    /*/
 
7. The payments described in Schedule D hereto constitute full and complete compensation for WALCO.
 
8. All returns shall be approved by Pfizer and subject to Pfizer’s Returned Goods Policy, attached hereto as Schedule F. WALCO may not offset payment to Pfizer of invoice amounts as credit for any compensation payable hereunder. Pfizer shall make bi-monthly payments of appropriate fees to WALCO.
 
9. WALCO and Pfizer agree that, under the specific circumstances delineated in this Section 9, each party, at such party’s sole discretion, may recoup the sums outstanding to it from the other party against those sums which may become due from such party to the other party, in that the obligations arise from mutual transactions. The specific circumstances which will enable each party to initiate recoupment are:
 
    (a) The other party becomes insolvent, which shall be defined as:
 
       (i) the sum of the other party’s debts is greater than all of other party’s property (“Balance Sheet Test”); or
 
       (ii) the other party is generally not paying its debts as they come due; or
 
       (iii) the other party has failed to act in good faith for a period in excess of six (6) months to resolve any outstanding invoice or purchase order issues or reconciliations.
 
 
 

 
    (b) The other party commences a liquidation of its operations by means of a sale of its assets in their entirety or piecemeal; or
 
    (c) The other party ceases its business operations whether or not such cessation is voluntary or involuntary; or;
 
    (d) The other party files a proceeding pursuant to the U.S. Bankruptcy Code or any state court proceeding, including an Assignment for the Benefit of Creditors.
 
10. Nothing in this Agreement shall be deemed to preclude WALCO from negotiating a service fee or any other consideration from, or providing any discount or rebate to, any customer, including PARTICIPATING CUSTOMERS for any services provided by WALCO.
 
11. WALCO shall distribute Pfizer Products only under the labeling provided by Pfizer or as otherwise approved in writing by Pfizer; prescribe, recommend, suggest, and advertise each Product for use only under the conditions stated in the labeling provided by Pfizer; and observe all federal, state, and local laws governing the distribution of the Products.
 
12. Nothing in this Agreement shall be deemed to limit Pfizer’s ability to sell any Product at any time to any customer including PARTICIPATING CUSTOMERS or any other party. Transactions consummated directly between Pfizer and any such customer or other party shall not qualify for any of the compensation payable to WALCO hereunder. Nothing in this Agreement shall be deemed to limit WALCO’s ability to sell non-Pfizer products at any time to any customer including PARTICIPATING CUSTOMERS or any other party. WALCO’s active promotion or sale of products not made by Pfizer will not be considered harmful to the Goodwill or name of Pfizer, or the Products, provided that the Pfizer Products are not maligned in any way as prohibited under Section 4(k) of this Agreement.
 
13. EXCEPT AS SET FORTH IN THIS AGREEMENT, IN THE LABELING OF THE PRODUCTS SOLD HEREUNDER, OR AS OTHERWISE SPECIFIED IN WRITING BY PFIZER, PFIZER MAKES NO EXPRESS OR IMPLIED WARRANTIES WITH RESPECT TO THE PRODUCTS.
 
    (a) Pfizer shall defend, indemnify, and hold WALCO harmless from all liabilities, claims, demands, damages, costs and expenses, or money judgments incurred by WALCO or rendered against it resulting from (a) any breach by Pfizer of this Agreement, (b) third party claims or actions for personal injury or property damage which arise out of the distribution or sale of Pfizer products or the failure to warn, except to the extent that such personal injury or property damage arises out of the negligence or willful misconduct of WALCO, and (c) any claim that the Products, as sold by Pfizer, were defective. In the event Pfizer is found by any court of competent jurisdiction to be liable for any claim based in products liability, then Pfizer shall reimburse WALCO’s reasonable legal fees incurred in the course of cooperating with Pfizer’s defense. To be covered by this defense and indemnity, WALCO must: promptly notify Pfizer of any such claim; allow Pfizer to fully control the defense and/or resolution of the claim; and cooperate fully with Pfizer in the matter. This defense, indemnity and payment for legal fees shall not apply to claims alleging: WALCO alteration, negligent handling or improper storage of the Products; sale of outdated Products; sale or recommendation of the Products for uses or in a manner not set forth in either the labeling supplied by Pfizer or as otherwise specified by Pfizer in writing; or sale of the Products after receipt of written notice from Pfizer that such sales should be halted.
 
    (b) In no event shall either party be liable to the other party for special, collateral, incidental, punitive or consequential damages in connection with or arising out of this Agreement. Except as provided under subparagraph 13(a), above, total damages recoverable against Pfizer by WALCO shall be exclusively limited to the purchase price of the Products with respect to which damages are claimed.
 
 
 

 
14. WALCO and Pfizer acknowledge that in the performance of their duties hereunder each may obtain access to "Confidential Information" (as defined below) of the other. WALCO and Pfizer agree that during the term of this Agreement and for a period of three (3) years after the termination of this Agreement, unless specifically permitted in writing by the other party, which permission shall not be unreasonably withheld, especially in connection with a sale of all or a substantial portion of WALCO’s business, to (a) retain in confidence and not disclose to any third party and (b) use only for the purpose of carrying out their duties hereunder, any such Confidential Information. As used herein the term "Confidential Information" means any information, or data, whether of a business or scientific nature and whether in written, oral or tangible form, relating to Pfizer’s and WALCO's business or potential business or its research and development activities, not generally available to or known to the public, and not otherwise known to the receiving party, that is disclosed to or learned by the other party pursuant hereto. "Confidential information" does not mean or include any information: (a) which is, at the time of disclosure, available to the general public; or (b) which following disclosure becomes available to the general public through no fault of the recipient; or (c) which recipient can demonstrate was in its possession before receipt; or (d) which is disclosed to recipient without restriction on disclosure. Upon written request from either party after completion of the work provided for hereunder or other termination of this Agreement each party will return to the other party any documents, or copies thereof, or any product samples, containing or constituting Confidential Information disclosed to or generated by either party in connection with this Agreement.
 
15. All notices or communications given hereunder by one party to the other shall be sent by hand or by first class prepaid registered or recorded delivery post or by facsimile addressed to such party as follows:
 
    If to Pfizer:
 
       Pfizer, Inc.
       Attention: President, Animal Health
       5 Giralda Farms
       Madison, New Jersey 07940-1027
 
    If to WALCO:
 
       Walco International, Inc.
       7 Village Circle, Suite 200
       Westlake, TX 76262
 
Either party may change its address by giving written notice to the other party.
 
16. This Agreement shall be effective as of January 1, 2011 and shall continue in force until December 31, 2011. This Agreement may be terminated by either party upon thirty (30) days prior written notice. Such termination may be without cause. This Agreement may be terminated immediately by either party upon written notice in the event of a material breach by the other. In the event WALCO takes any action that harms or damages the interests of Pfizer or the Products, other than where supported by sound factual evidence, including, but not limited to, the diversion of Products and statements of false information, Pfizer may terminate this Agreement immediately upon written notice.
 
17. This Agreement shall be governed by the laws of the State of New York applicable to contracts made and performed therein. This Agreement is not assignable without the express written consent of the other party, and may be modified or amended only in writing signed by both parties.
 
18. This Agreement and documents referred to herein embody the entire understanding between the parties hereto, will supersede prior agreements relating to the Products. No activities conducted pursuant to this Agreement or related thereto, including but not limited to the future planning activities of the parties, shall be deemed to give rise to any obligations on the part of either party other than as expressly provided for herein.
 
    IN WITNESS WHEREOF, intending to be legally bound, the parties have executed this Agreement.
 
Walco International, Inc.
Pfizer Inc.
   
By /s/ Clinton A. Lewis, Jr.
   Damian Othoff
   Clinton A. Lewis, Jr.
   General Counsel
   President, U.S. Operations
 
   Pfizer Animal Health
   
Date February 2, 2011
Date February 28, 2011
 
 
 

 
SCHEDULE A
 
FEE ELIGIBLE PRODUCTS

 
 
 2011 Leaders' Edge RSA Eligibility List
 
SKU  ITEM DESCRIPTION   SIZE RSA ELIGIBLE  RSA (Sales to LE Vets & Animal Health Accounts)   RSA (Sales to Strategic Producers)   RSA Sales to LE Producers
      CATTLE-BIOLOGICALS
4252
Bovi-Shield® BRSV
 
10
/*/
/*/
/*/
/*/
4256
Bovi-Shield BRSV
 
50
/*/
/*/
/*/
/*/
5194
Bovi-Shield GOLD® 4
 
10
/*/
/*/
/*/
/*/
5195
Bovi-Shield GOLD 4
 
50
/*/
/*/
/*/
/*/
5199
Bovi-Shield GOLD® 5
 
5
/*/
/*/
/*/
/*/
5196
Bovi-Shield GOLD 5
 
10
/*/
/*/
/*/
/*/
5197
Bovi-Shield GOLD 5
 
50
/*/
/*/
/*/
/*/
5321
Bovi-Shield GOLD® FP® 5**
 
10
/*/
/*/
/*/
/*/
5322
Bovi-Shield GOLD FP 5**
 
50
/*/
/*/
/*/
/*/
5114
Bovi-Shield GOLD FP 5 L5*
 
50
/*/
/*/
/*/
/*/
5323
Bovi-Shield GOLD® FP® 5 L5**
 
5
/*/
/*/
/*/
/*/
5324
Bovi-Shield GOLD FP 5 L5**
 
10
/*/
/*/
/*/
/*/
5325
Bovi-Shield GOLD FP 5 L5**
 
50
/*/
/*/
/*/
/*/
5116
Bovi-Shield GOLD FP 5 VL5*
 
50
/*/
/*/
/*/
/*/
5326
Bovi-Shield GOLD® FP® 5 VL5**
 
10
/*/
/*/
/*/
/*/
5327
Bovi-Shield GOLD FP 5 VL5**
 
50
/*/
/*/
/*/
/*/
5044  Bovi-Shield GOLD® FP® 5L5 HB  
/*/
 /*/ /*/   /*/
 5253 Bovi-Shield GOLD FP 5 L5 HB     10 /*/   /*/  /*/ /*/ 
5254
Bovi-Shield GOLD FP 5 L5 HB
 
50
/*/
/*/
/*/
/*/
5255
Bovi-Shield GOLD® FP® 5 VL5 HB
 
10
/*/
/*/
/*/
/*/
5256
Bovi-Shield GOLD FP 5 VL5 HB
 
50
/*/
/*/
/*/
/*/
 5267 Bovi-Shield GOLD® BVD     10  /*/ /*/  /*/  /*/ 
 5268  Bovi-Shield GOLD BVD   50   /*/  /*/ /*/   /*/
 5269 Bovi-Shield GOLD® IBR-BVD     10  /*/ /*/   /*/  /*/
5191
Bovi-Shield GOLD® IBR-BVD
 
50
/*/
/*/
/*/
/*/
4179
Bovi-Shield® IBR
 
50
/*/
/*/
/*/
/*/
4002
Calf-Guard®
 
1
/*/
/*/
/*/
/*/
4143
CattleMaster® 4+VL5
 
5
/*/
/*/
/*/
/*/
4144
CattleMaster 4+VL5
 
10
/*/
/*/
/*/
/*/
4145
CattleMaster 4+VL5
 
25
/*/
/*/
/*/
/*/
5094
CattleMaster® GOLD™ FP® 5
 
5
/*/
/*/
/*/
/*/
5095
CattleMaster GOLD FP 5
 
10
/*/
/*/
/*/
/*/
5096
CattleMaster GOLD FP 5
 
25
/*/
/*/
/*/
/*/
5124
CattleMaster® GOLD™ FP® 5 L5
 
5
/*/
/*/
/*/
/*/
5125
CattleMaster GOLD FP 5 L5
 
10
/*/
/*/
/*/
/*/
5126
CattleMaster GOLD FP 5 L5
 
25
/*/
/*/
/*/
/*/
1434
E.coli Bacterin- J-5™ Strain
 
20
/*/
/*/
/*/
/*/
1435
E.coli Bacterin- J-5 Strain
 
50
/*/
/*/
/*/
/*/
 5263 INFORCE™3     1
/*/
/*/  /*/   /*/
 
 
 
 

 
 
 
 5264 INFORCE 3     10  /*/  /*/ /*/   /*/
 5265 INFORCE 3     25  /*/  /*/ /*/   /*/
 5266 INFORCE 3     50  /*/  /*/ /*/   /*/
4475
Leptoferm-5®
 
10
/*/
/*/
/*/
/*/
4477
Leptoferm-5
 
50
/*/
/*/
/*/
/*/
4988
One Shot®
 
5
/*/
/*/
/*/
/*/
4991
One Shot
 
10
/*/
/*/
/*/
/*/
4993
One Shot
 
50
/*/
/*/
/*/
/*/
5074
One Shot Ultra® 7
 
10
/*/
/*/
/*/
/*/
5075
One Shot Ultra 7
 
50
/*/
/*/
/*/
/*/
5076
One Shot Ultra® 8
 
10
/*/
/*/
/*/
/*/
5077
One Shot Ultra 8
 
50
/*/
/*/
/*/
/*/
5328
PregGuard® GOLD FP® 10**
 
10
/*/
/*/
/*/
/*/
5329
PregGuard GOLD FP 10**
 
50
/*/
/*/
/*/
/*/
4308
Resvac® 4/Somubac®
 
10
/*/
/*/
/*/
/*/
4307
Resvac 4/Somubac
 
50
/*/
/*/
/*/
/*/
5331
ScourGuard® 4K**
 
10
/*/
/*/
/*/
/*/
5332
ScourGuard 4K**
 
50
/*/
/*/
/*/
/*/
5333
ScourGuard® 4KC**
 
10
/*/
/*/
/*/
/*/
5334
ScourGuard 4KC**
 
50
/*/
/*/
/*/
/*/
4255
Somubac®
 
10
/*/
/*/
/*/
/*/
4254
Somubac
 
50
/*/
/*/
/*/
/*/
5088
Spirovac®
 
10
/*/
/*/
/*/
/*/
5090
Spirovac
 
50
/*/
/*/
/*/
/*/
5200
Spirovac® L5
 
10
/*/
/*/
/*/
/*/
5201
Spirovac L5
 
50
/*/
/*/
/*/
/*/
5202
Spirovac® VL5
 
10
/*/
/*/
/*/
/*/
5203
Spirovac VL5
 
50
/*/
/*/
/*/
/*/
4890
StayBred™ VL5
 
10
/*/
/*/
/*/
/*/
4892
StayBred VL5
 
50
/*/
/*/
/*/
/*/
4904
TSV-2®
 
1
/*/
/*/
/*/
/*/
4909
TSV-2
 
10
/*/
/*/
/*/
/*/
4912
TSV-2
 
25
/*/
/*/
/*/
/*/
4913
TSV-2
 
50
/*/
/*/
/*/
/*/
4381
Ultrabac® 7
 
10
/*/
/*/
/*/
/*/
4379
Ultrabac 7
 
50
/*/
/*/
/*/
/*/
4380
Ultrabac 7
 
200
/*/
/*/
/*/
/*/
4384
Ultrabac® 7/Somubac®
 
10
/*/
/*/
/*/
/*/
4382
Ultrabac 7/Somubac
 
50
/*/
/*/
/*/
/*/
4383
Ultrabac 7/Somubac
 
200
/*/
/*/
/*/
/*/
4387
Ultrabac-8®
 
10
/*/
/*/
/*/
/*/
4385
Ultrabac-8
 
50
/*/
/*/
/*/
/*/
4386
Ultrabac-8
 
200
/*/
/*/
/*/
/*/
4388
Ultrabac® CD
 
10
/*/
/*/
/*/
/*/
4371
Ultrabac CD
 
50
/*/
/*/
/*/
/*/
5062
UltraChoice® 7
 
10
/*/
/*/
/*/
/*/
5063
UltraChoice 7
 
50
/*/
/*/
/*/
/*/
5064
UltraChoice 7
 
250
/*/
/*/
/*/
/*/
5065
UltraChoice® 8
 
10
/*/
/*/
/*/
/*/
5066
UltraChoice 8
 
50
/*/
/*/
/*/
/*/

 
 

 
5067
UltraChoice 8
 
250
/*/
/*/
/*/
/*/
5061
UltraChoice® CD
 
50
/*/
/*/
/*/
/*/
4937
Vibrin®
 
50
/*/
/*/
/*/
/*/
5330
SolidBac® Pinkeye IR/PR®
 
1 Pouch of 50
/*/
/*/
/*/
/*/
 5270 Salmonella NewPort Bacterial Extract     50
/*/
/*/
/*/
/*/
 5271 Escherichia Coli Bacterial Extract     50
/*/
/*/
/*/
/*/
CATTLE-ANTI-INFECTIVES
           
8171
A180®
Rx
100 mL
/*/
/*/
/*/
 
/*/
8172
A180
Rx
250 mL
/*/
/*/
/*/
 
/*/
8448
Albon® Bolus
 
5 g x 50
/*/
/*/
/*/
 
/*/
8449
Albon Bolus
 
15 g x 12
/*/
/*/
/*/
 
/*/
8450
Albon Bolus
 
15 g x 50
/*/
/*/
/*/
 
/*/
8189
Draxxin® Injectable Solution
Rx
50 mL
/*/
/*/
/*/
 
/*/
8174
Draxxin Injectable Solution
Rx
100 mL
/*/
/*/
/*/
 
/*/
8175
Draxxin Injectable Solution
Rx
250 mL
/*/
/*/
/*/
 
/*/
8176
Draxxin Injectable Solution
Rx
500 mL
/*/
/*/
/*/
 
/*/
1506
Excede® Sterile Suspension
Rx
100 mL
/*/
/*/
/*/
 
/*/
1431
Excenel® RTU Sterile Suspension
Rx
100 mL
/*/
/*/
/*/
 
/*/
7959
Liquamycin® LA-200®
 
100 mL
/*/
/*/
/*/
 
/*/
7960
Liquamycin LA-200
 
250 mL
/*/
/*/
/*/
 
/*/
7961
Liquamycin LA-200
 
500 mL
/*/
/*/
/*/
 
/*/
1465
Naxcel® Sterile Powder
Rx
1 g
/*/
/*/
/*/
 
/*/
1466
Naxcel Sterile Powder
Rx
4 g
/*/
/*/
/*/
 
/*/
1463
Sterile Water
 
80 mL
/*/
/*/
/*/
 
/*/
 1464 Sterile Water     20 mL  /*/
/*/
/*/
 
/*/
7948
Terramycin® Scour Tabs
 
250 mg, 24/btl
/*/
/*/
/*/
 
/*/
7949
Terramycin Scour Tabs
 
250 mg, 100/btl
/*/
/*/
/*/
 
/*/
CATTLE-LINCOMIX
           
1452
Lincomix® Soluble Powder
 
160 g
/*/
/*/
/*/
 
/*/
1436
Linco-Spectin®
Rx
20 mL
/*/
/*/
/*/
 
/*/
CATTLE-MASTITIS
           
1403
Albadry Plus®
 
12
/*/
/*/
/*/
 
/*/
1404
Albadry Plus
 
144
/*/
/*/
/*/
 
/*/
2004
Nolvasan® Teat Dip
 
1 gal
/*/
/*/
/*/
 
/*/
8169
Orbeseal®
 
144
/*/
/*/
/*/
 
/*/
1475
Pirsue® Sterile Solution
Rx
12
/*/
/*/
/*/
 
/*/
1476
Pirsue Sterile Solution
Rx
144
/*/
/*/
/*/
 
/*/
1480
Quartermaster®
Rx
12
/*/
/*/
/*/
 
/*/
1481
Quartermaster (Bulk Pack)
Rx
144
/*/
/*/
/*/
 
/*/
1507
Spectramast® LC
Rx
12
/*/
/*/
/*/
 
/*/
1510
Spectramast LC
Rx
144
/*/
/*/
/*/
 
/*/
1508
Spectramast® DC
Rx
12
/*/
/*/
/*/
 
/*/
1511
Spectramast DC
Rx
144
/*/
/*/
/*/
 
/*/
CATTLE-PARACITICIDES
           
7897
Dectomax® 1% Injectable
 
100 mL
/*/
/*/
/*/
 
/*/
8186
Dectomax 1% Injectable
 
200 mL
/*/
/*/
/*/
 
/*/
7899
Dectomax 1% Injectable
 
500 mL
/*/
/*/
/*/
 
/*/
7892
Dectomax® Pour-On
 
250 mL
/*/
/*/
/*/
 
/*/
7893
Dectomax Pour-On
 
1 L
/*/
/*/
/*/
 
/*/
7894
Dectomax Pour-On
 
2.5 L
/*/
/*/
/*/
 
/*/
7895
Dectomax Pour-On
 
5 L
/*/
/*/
/*/
 
/*/
7030
Durasect®
 
1 gal
/*/
/*/
/*/
 
/*/
7032
Durasect II
 
900 mL
/*/
/*/
/*/
 
/*/
8783
Valbazen®
 
500 mL
/*/
/*/
/*/
 
/*/

 
 

 
8784
Valbazen
 
1 L
/*/
/*/
/*/
/*/
8785
Valbazen
 
5 L
/*/
/*/
/*/
/*/
CATTLE-REPRODUCTION
           
1420
EAZI-Breed™ CIDR® Applicator
 
Applicator
/*/
/*/
/*/
/*/
1518
EAZI-Breed CIDR Green Applicator
 
Applicator
/*/
/*/
/*/
/*/
1421
EAZI-Breed CIDR Insert
 
Bag of 10
/*/
/*/
/*/
/*/
0135
EAZI-Breed™ CIDR® G Applicator (Sheep)
 
Applicator
/*/
/*/
/*/
/*/
1533
EAZI-Breed CIDR G Insert (Sheep)
 
Bag of 20
/*/
/*/
/*/
/*/
2001
Factrel®
Rx
20 mL
/*/
/*/
/*/
/*/
1455
Lutalyse® Sterile Solution
Rx
30 mL
/*/
/*/
/*/
/*/
1504
Lutalyse Sterile Solution
Rx
100 mL
/*/
/*/
/*/
/*/
2003
Nolvalube®
 
8 lb
/*/
/*/
/*/
/*/
CATTLE-OTHER PHARMACEUTICALS
           
8152
Entrolyte® H.E.
 
178 g
/*/
/*/
/*/
/*/
2002
Hog & Cattle Vitamins & Electrolytes
 
8 oz
/*/
/*/
/*/
/*/
1478
Predef® 2X
Rx
100 mL
/*/
/*/
/*/
/*/
8112
Re-Sorb®
 
12
/*/
/*/
/*/
/*/
8142
Re-Sorb
 
72
/*/
/*/
/*/
/*/
8620
Therabloat®
 
2 oz
/*/
/*/
/*/
/*/
CATTLE-PRODUCTION
           
1458
MGA® 200 Premix
 
50 lb bag
/*/
/*/
/*/
/*/
1459
MGA® 500 Liquid Premix
 
40 lb drum
/*/
/*/
/*/
/*/
2016
Synovex® C
 
Box(10-10 ds Clips)
/*/
/*/
/*/
/*/
2014
Synovex C
 
Display(20 x 2-10 ds Clips)
/*/
/*/
/*/
/*/
2017
Synovex® Choice
 
Box(10-10 ds Clips)
/*/
/*/
/*/
/*/
2018
Synovex® H
 
Box(10-10 ds Clips)
/*/
/*/
/*/
/*/
2019
Synovex® Plus
 
Box(10-10 ds Clips)
/*/
/*/
/*/
/*/
2022
Synovex® S
 
Box(10-10 ds Clips)
/*/
/*/
/*/
/*/
   DAIRY GENOMICS            
 PAG3KDB Brown Swiss 3K Core Traits     -  /*/  /*/  /*/  /*/
 PAG3KDH Holstein 3K Core Traits     -  /*/  /*/  /*/  /*/
 PAG3KDJ Jersey 3K Core Traits     -  /*/  /*/  /*/  /*/
 PAGR Dairy Red Carrier Test     /*/   /*/ /*/  /*/ 
  BEEF GENOMICS            
 PAGHDA High Density 50 K Angus     -  /*/  /*/ /*/   /*/
 PAGGST GeneSTAR Combined Paned     -  /*/  /*/  /*/  /*/
 PAGB GeneSTAR Black     -  /*/ /*/   /*/ /*/ 
   GENETIC CONDITIONS            
PAGDEFAM Anthrogryposis Mulitplex     -  /*/  /*/ /*/   /*/
 PAGDEFNH Neuro Hydrocephalus     -  /*/  /*/  /*/  /*/
 PAGDEFAMNH AM and NH Combined     -  /*/  /*/  /*/  /*/
 PAGDEFCA Contractural Arachnodactyly     -  /*/  /*/  /*/  /*/
 PAGDEFIE Idiopathic Epilepsy     -  /*/  /*/  /*/  /*/
 PAGDEFMA Alpha-Mannisodosis     -  /*/  /*/  /*/  /*/
 PAGDEFOS Osteopetrosis     -  /*/  /*/  /*/  /*/
 PAGDEFPH Pulmonary Hyperplasia Anasarca     -  /*/  /*/  /*/  /*/
 PAGDEFTH Tibial Hemimelia     -  /*/  /*/  /*/  /*/
 PAGDEFPHTH PH and TH     -  /*/ /*/   /*/ /*/ 
   PARENT VERIFICATION            
 PAGPSNP SireTRACE (SNP)     - /*/  /*/ /*/  /*/ 
SWINE RESPIRATORY BIOLOGICALS
           
5223
FluSure XP®
 
50
/*/
/*/
/*/
/*/
5224
FluSure XP
 
250
/*/
/*/
/*/
/*/
5042
FluSure® Pandemic
 
50
/*/
/*/
/*/
/*/
5043
FluSure Pandemic
 
250
/*/
/*/
/*/
/*/
5219
FluSure XP®/FarrowSure® GOLD
 
50
/*/
/*/
/*/
/*/
5220
FluSure XP/FarrowSure GOLD
 
250
/*/
/*/
/*/
/*/
5221
FluSure XP®/FarrowSure® GOLD Plus B
 
50
/*/
/*/
/*/
/*/
5227
FluSure XP®/RespiSure®
 
50
/*/
/*/
/*/
/*/
5231
FluSure XP®/RespiSure-ONE®
 
50
/*/
/*/
/*/
/*/
5225
FluSure XP®/ER Bac Plus®
 
50
/*/
/*/
/*/
/*/
5233
FluSure XP®/RespiSure-ONE®/ER Bac Plus®
 
50
/*/
/*/
/*/
/*/
5001
RespiSure-ONE® (to be disc)
 
50
/*/
/*/
/*/
/*/
5002
RespiSure-ONE (to be disc)
 
250
/*/
/*/
/*/
/*/
5003
RespiSure-ONE (to be disc)
 
500
/*/
/*/
/*/
/*/
 5260 RespiSure-ONE®     50  /*/  /*/  /*/  /*/
 5261 RespiSure-ONE     250  /*/  /*/  /*/ /*/ 
 5262 RespiSure-ONE     500  /*/  /*/  /*/  /*/
5166
RespiSure-ONE®/ER Bac Plus®
 
50
/*/
/*/
/*/
/*/
5167
RespiSure-ONE/ER Bac Plus
 
250
/*/
/*/
/*/
/*/
5168
RespiSure-ONE/ER Bac Plus
 
500
/*/
/*/
/*/
/*/
4606
RespiSure®
 
50
/*/
/*/
/*/
/*/

 
 

 
4618
RespiSure
 
250
/*/
/*/
/*/
/*/
4589
RespiSure
 
500
/*/
/*/
/*/
/*/
5169
RespiSure®/ER Bac Plus®
 
50
/*/
/*/
/*/
/*/
5170
RespiSure/ER Bac Plus
 
250
/*/
/*/
/*/
/*/
5171
RespiSure/ER Bac Plus
 
500
/*/
/*/
/*/
/*/
2238
Suvaxyn® RespiFend® MH/HPS
 
50
/*/
/*/
/*/
/*/
2239
Suvaxyn RespiFend MH/HPS
 
125
/*/
/*/
/*/
/*/
2224
Suvaxyn® PCV2
 
50
/*/
/*/
/*/
/*/
2225
Suvaxyn PCV2
 
250
/*/
/*/
/*/
/*/
5041
ER Bac® Plus
 
250
/*/
/*/
/*/
/*/
2214
Suvaxyn® E - oral
 
100
/*/
/*/
/*/
/*/
2215
Suvaxyn E - oral
 
250
/*/
/*/
/*/
/*/
2216
Suvaxyn E - oral
 
500
/*/
/*/
/*/
/*/
SWINE REPRODUCTIVE BIOLOGICALS
           
5213
ER Bac® L5 GOLD
 
50
/*/
/*/
/*/
/*/
5204
FarrowSure® GOLD
 
50
/*/
/*/
/*/
/*/
5248
FarrowSure GOLD
 
250
/*/
/*/
/*/
/*/
5206
FarrowSure® GOLD B
 
50
/*/
/*/
/*/
/*/
4402
LitterGuard®
 
50
/*/
/*/
/*/
/*/
4410
LitterGuard® LT-C
 
50
/*/
/*/
/*/
/*/
4452
LitterGuard LT-C
 
250
/*/
/*/
/*/
/*/
SWINE LARGE ANIMAL VIALS
           
8189
Draxxin® Injectable Solution
Rx
50 mL
/*/
/*/
/*/
/*/
8174
Draxxin Injectable Solution
Rx
100 mL
/*/
/*/
/*/
/*/
8175
Draxxin Injectable Solution
Rx
250 mL
/*/
/*/
/*/
/*/
8176
Draxxin Injectable Solution
Rx
500 mL
/*/
/*/
/*/
/*/
1505
EXCEDE® for Swine
Rx
100 mL
/*/
/*/
/*/
/*/
1431
Excenel® RTU Sterile Suspension
Rx
100 mL
/*/
/*/
/*/
/*/
1436
Linco-Spectin®
Rx
20 mL
/*/
/*/
/*/
/*/
1450
Lincomix® 100 mg Injectable
 
100 mL
/*/
/*/
/*/
/*/
1451
Lincomix 300 mg Injectable
 
100 mL
/*/
/*/
/*/
/*/
1455
Lutalyse® Sterile Solution
Rx
30 mL
/*/
/*/
/*/
/*/
1504
Lutalyse Sterile Solution
Rx
100 mL
/*/
/*/
/*/
/*/
1465
Naxcel® Sterile Powder
Rx
1 g
/*/
/*/
/*/
/*/
1466
Naxcel Sterile Powder
Rx
4 g
/*/
/*/
/*/
/*/
1463
Sterile Water
 
80 mL
/*/
/*/
/*/
/*/
1478
Predef® 2X
Rx
100 mL
/*/
/*/
/*/
/*/

 
 

 
7897
Dectomax® 1% Injectable
 
100 mL
/*/
/*/
/*/
/*/
8186
Dectomax 1% Injectable
 
200 mL
/*/
/*/
/*/
/*/
7899
Dectomax 1% Injectable
 
500 mL
/*/
/*/
/*/
/*/
7959
Liquamycin® LA-200®
 
100 mL
/*/
/*/
/*/
/*/
7960
Liquamycin LA-200
 
250 mL
/*/
/*/
/*/
/*/
7961
Liquamycin LA-200
 
500 mL
/*/
/*/
/*/
/*/
1453
Lincomix Soluble Powder
 
480 g
/*/
/*/
/*/
/*/
1454
LS 50
 
75 g
/*/
/*/
/*/
/*/
SWINE-FEED MEDICATIONS
       
1447
Lincomix® 20
 
50 lb
/*/
/*/
/*/
/*/
1448
Lincomix® 50
 
50 lb
/*/
/*/
/*/
/*/
*Product skus will be discontinued once inventory is depleted.   
**Product skus will become available once inventory of old skus is depleted.
       

 
 

 

SCHEDULE B
 
LIST OF STRATEGIC ACCOUNTS
 
“PARTICIPATING CUSTOMERS (Veterinarians, Dealers, Producers, and Strategic Producers) will be clearly identified with current updates within the LeadersEdge Enrollment Notifications that are regularly posted to the Pfizer AH Partners website www.pfizerahartners.com.
 
Narc ID
Name
Address
City
State
/*/  /*/  /*/  /*/  /*/
 
 
 
 

 

SCHEDULE C
 
SUGGESTED RESALE PRICE LIST AND DISTRIBUTOR PRICING
CATTLE SUGGESTED RETAIL PRICING
 
Pricing will be provided by Pfizer as specified herein.
 
 

 

SCHEDULE D
 
Section A
 
Fee for Logistics
 
Definitions:
“Fee Eligible Products” shall mean those Pfizer Products listed in Schedule A hereto for which a Fee payment will be made to WALCO in accordance with paragraph 5.
 
1) Pfizer shall pay to WALCO a fee for logistics (hereinafter, “Fee”) paid at a rate of (i) a differentiated percentage [see SCHEDULE E for breakdown] on Sales Out for Fee Eligible Products to identified PARTICIPATING CUSTOMERS who are producers (but not including Strategic Accounts), (ii) /*/ on Sales Out for Fee Eligible Products to identified PARTICIPATING CUSTOMERS who are veterinarians (but not including Strategic Accounts), and (iii) /*/  on Sales Out for Fee Eligible Products to identified PARTICIPATING CUSTOMERS who are Strategic Accounts.  For a Veterinarian to receive an RSA on Strategic Producer product sales, the Veterinarian must buy those product quantities directly from Pfizer Animal Health.  Such product purchases must be made within the timeframe of the reported sales to the Strategic Producer in order to receive a /*/ RSA for sales to Leaders’ Edge Strategic Producers.  The Veterinarian also must hold the accounts receivable on those products for the Strategic Producer.  The remaining product purchases to service Leaders’ Edge accounts or Non-Leaders’ Edge accounts may be sourced from an authorized Pfizer distributor or directly from Pfizer Animal Health.  The Fee is calculated on a Product by Product basis and based on the Product price contained in the Participating Customer’s SUGGESTED RESALE PRICE LIST in effect at the time of such Product purchase. The Fee is contingent on WALCO fulfilling all conditions outlined in paragraph 4 of this Agreement.  The payments made pursuant to this Schedule D, Section A are not payable for sales to anyone other than PARTICIPATING CUSTOMERS.  The Fee is net of any difference between WALCO’s purchase price and the SUGGESTED RESALE PRICE LIST price.  WALCO shall only receive the payments set out in this Schedule D, Section A for sales to PARTICIPATING CUSTOMERS which are consummated after confirmation by Pfizer to WALCO that a customer is a PARTICIPATING CUSTOMER.
 
2) Pfizer shall have the right to audit shipping records of WALCO to confirm delivery of Products to producers or veterinarians in order to assure proper Fee payments under paragraph 1 of this Schedule D, Section A.  Any material misrepresentations by WALCO related to paragraph 1 of this Schedule D, Section A and the party actually taking possession of the products shall void any payments due under paragraph 1 of this Schedule D, Section A. In addition, WALCO recognizes that the Leaders Edge program is designed as an effective go-to market approach to selling for the benefit of veterinarians and/or dealers who add value in the transaction to their customers as well as value for those customers.  Blatant abuse of the intended structure of the Leaders Edge Program by WALCO (including, but not limited to, falsification of EDI data or establishing false business entities or inserting business entities that add no commercial value to end users purely to obtain additional Fee payments) will subject WALCO to potential forfeiture of all Fee’s paid on those transactions provided for in this Schedule D, Section A at the sole discretion of Pfizer.  Decisions made as a result of Pfizer’s investigations of blatant abuse of the intended structure of Leaders Edge are solely Pfizer’s to make and forfeitures of Fees may happen retroactively in the form of credits against future Fee payments.
 
3) The parties agree that WALCO will provide to Pfizer on request and within two (2) business days, proof of delivery on any suspicious (as determined by Pfizer) EDI transaction.  WALCO agrees that Pfizer shall be entitled to audit, either directly or through external auditors hired by Pfizer and upon reasonable notice by Pfizer, WALCO’s books and records for the purpose of determining the accuracy of EDI data for Pfizer Product sales communicated to Pfizer through Covansys.
 
4) Products which are not listed in Schedule A do not qualify for Fee payments.  All such Products shall be purchased by WALCO on a buy sell basis.  If new sku’s are added to Schedule A, Pfizer will communicate this to WALCO on a quarterly basis.
 
 
 

 
SCHEDULE E
 
Cattle Swine Leaders Edge/Differentiated RSA
 
Effective January 1, 2011 through December 31, 2011 Leaders’ Edge Suppliers will receive a service fee (RSA) for sales to eligible Leaders’ Edge customers as indicated below.
 
RSA Payments
Sales To ->
LE Vet/Dealer
LE Strategic Producer
LE Producer
Distributor
/*/
/*/
Variable RSA (See Schedule A)
Veterinarian
/*/
/*/*
Variable RSA (See Schedule A)

** Veterinarians MUST purchase an equivalent amount of product direct from Pfizer Animal Health to be eligible for a /*/ RSA for sales to Leaders’ Edge Strategic Producers.



 
 

 
SCHEDULE F
 
Pfizer Returned Goods Policy & Procedure
 
AUDIENCE
 
  Customer Service Operations, Finance, Marketing, & Field Force
 
SCOPE
 
Cattle, Swine, Equine, and CAD products purchased directly from Pfizer Animal Health may be returned for credit based on the current Pfizer Animal Health Return Goods Price List providing it is not outside the defined return window.  ONLY CAD products may be returned for exchange providing it is not outside the defined return window.
 
   o  Cattle, Swine, Equine, and CAD products return window is defined as two months prior and six months beyond the product’s expiration date. (except Revolution 6pk and Rimadyl 180ct, which can be exchanged or credited six months prior to the products expiration date).
   o    In addition, CAD products may also be returned 12 months after the  invoice date for Return Goods Credit only provided that the product has not expired.

Cattle, Swine, and Equine Biologicals purchased directly from Pfizer Animal Health may be returned for credit based upon 100% of the customer’s prior calendar year’s pricing.  All other Cattle, Swine, and Equine products will receive credit based upon 90% of the customer’s prior calendar year’s pricing.
 
   o   Exception #1: Short dated products (defined as consistently shipping with 4-6months dating or less, such as ScourGuard) may receive a return goods credit based upon 100% of customer’s current year’s pricing.
   o  Exception #2: Newly launched products not available the prior year, will follow the return policy as stated above but pricing will be based off of the current year.
 
Cad Products purchased directly from Pfizer Animal Health may be returned for credit at 75% of current list price or be exchanged for like product in full packaged quantities provided they are within the return window.
 
   o  Exception #1:  Customers that receive discount pricing due to a contract may have terms per their contract stating they will receive returns pricing at 75% of invoice price.
 
Products sold on a non-returnable basis are not eligible for credit or exchange.  Products sold on a non-returnable basis include: syringes, rabies tags, Unipet Nutritabs, Roccal-D, Plastic Dispensing Bags, Sterile Water, Terramycin-343, Terramycin Soluble Powder, Eazi-Breed CIDR, Lincomix Soluble Powder, Lincomix Feed, Neomix 325 Commercial Grade, LS 50, and MGA
 
A. Products NOT eligible for exchange include:
 
1 Products not purchased directly from Pfizer Animal Health  
2 Cattle, Swine, and Equine Products  
3 Products outside the defined return window
4 Items returned in less than the original packaged unit (partials)  
 
B. Products NOT eligible for credit include:
 
1 Products not purchased directly from Pfizer Animal Health  
2 Products outside the defined return window
3 Items returned in quantities less than the original packaged unit (partials), with the exception of small animal biologicals, Amoxi tablets, Clavamox tablets, Albon tablets, Primor, Zeniquin, Cestex, Anipryl, and Temaril-P. Partial returns of these items will be credited in 25% increments.
 
C. Claims for Breakage or Shortage - Any obvious breakage or shortage must be brought to the attention of Pfizer Animal Health and the carrier. This must also be noted when signing delivery documents.  Mis-shipments, shortages and concealed damages must be reported to Pfizer Animal Health within 15 business days for distribution (21 days for Veterinarians) from invoice date to receive full invoice credit. Claims received after this timeframe will not be considered for credit. Credits for damages and mis-shipments (i.e. CSR or warehouse error) will be matched up to the original invoice and credited at full invoice pricing.
 
D. Discontinued Products - Discontinued products may not be returned for exchange but can be returned for credit at our current return’s price. Return of discontinued product must meet all other return requirements detailed in this policy.
 
PROCEDURE
 
Pfizer AH Customer Service will make pick up arrangements for returns of outdated product   purchased directly from Pfizer. Veterinarians or Pfizer Territory Managers should contact Customer Service to arrange for pick-up at 1-800-733-5500.  Returns for all other classes of trade should be sent freight prepaid to the Pfizer Returns Center located in Lee’s Summit, MO.
 
Customer Service and/or Pfizer Animal Health Territory Manager must complete the Merchandise Return Form (MRF) and forward along with the return shipment to the Pfizer Animal Health Returns Center at One Pfizer Way, Building 200, Lee’s Summit, MO 64081. The MRF should be marked as credit or exchange. If the return shipment contains both product to be credited, and also product to be exchanged, a separate MRF should be completed for the credit and the exchange.  Credit or exchange will be issued only upon receipt of the product at the Pfizer Animal Health Returns Center.  Product should not be destroyed in the field.  The product must have been purchased directly from Pfizer Animal Health and within the defined returns window.
 
Distributor accounts should fax a copy of the completed MRF to Major Accounts at 1-800-228-5176 for returns authorization.  Once approved, a copy of the signed form will be faxed back to the distributor to be included in the return shipment.